Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit.

Sun JB, Czerkinsky C, Holmgren J.

Scand J Immunol. 2010 Jan;71(1):1-11. doi: 10.1111/j.1365-3083.2009.02321.x. Review.

2.
3.
4.
6.
7.

Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.

Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, Mizushima Y, Holmgren J, Lehner T.

Clin Exp Immunol. 2004 Jul;137(1):201-8.

8.
9.

Oral tolerance: therapeutic implications for autoimmune diseases.

Faria AM, Weiner HL.

Clin Dev Immunol. 2006 Jun-Dec;13(2-4):143-57. Review.

10.

Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis.

Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, Ketelhuth DF, Gerdes N, Holmgren J, Nilsson J, Hansson GK.

Arterioscler Thromb Vasc Biol. 2010 May;30(5):946-52. doi: 10.1161/ATVBAHA.109.202671. Epub 2010 Feb 18.

11.

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

Holmgren J, Harandi AM, Czerkinsky C.

Expert Rev Vaccines. 2003 Apr;2(2):205-17. Review.

PMID:
12899572
12.
13.

Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells.

Ploix C, Bergerot I, Durand A, Czerkinsky C, Holmgren J, Thivolet C.

Diabetes. 1999 Nov;48(11):2150-6.

PMID:
10535448
14.

Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice.

Rask C, Holmgren J, Fredriksson M, Lindblad M, Nordström I, Sun JB, Czerkinsky C.

Clin Exp Allergy. 2000 Jul;30(7):1024-32.

PMID:
10848926
15.

The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes.

Bregenholt S, Wang M, Wolfe T, Hughes A, Baerentzen L, Dyrberg T, von Herrath MG, Petersen JS.

Scand J Immunol. 2003 May;57(5):432-8.

16.

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S.

Immunol Lett. 2005 Mar 15;97(2):181-8. Epub 2004 Dec 7. Review.

PMID:
15752556
17.

Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells.

George Chandy A, Hultkrantz S, Raghavan S, Czerkinsky C, Lebens M, Telemo E, Holmgren J.

Immunology. 2006 Jul;118(3):311-20.

18.

Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses.

Kato H, Fujihashi K, Kato R, Yuki Y, McGhee JR.

J Immunol. 2001 Mar 1;166(5):3114-21.

19.

Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin.

Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuère F.

J Immunol. 2006 Mar 1;176(5):2749-57.

20.

Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.

Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, Rottiers P.

Gastroenterology. 2007 Aug;133(2):517-28. Epub 2007 May 3.

PMID:
17681173

Supplemental Content

Support Center